Clinical validation of a multi-modal Ataraxis AI platform for recurrence prediction in early-stage breast cancer across multiple patient cohorts.
Witowski J, Choucair K, Elayoubi J, Chiru E, Chan N, Kang Y, Howard F, Ostrovnaya I, Schnabel F, Abdulsattar W, Zong Y, Daoud L, Vetter M, Pan J, Laurinavičius A, Piening B, Bifulco C, Brufsky A, Esteva F, Pusztai L. Clinical validation of a multi-modal Ataraxis AI platform for recurrence prediction in early-stage breast cancer across multiple patient cohorts. Journal Of Clinical Oncology 2025, 43: 549-549. DOI: 10.1200/jco.2025.43.16_suppl.549.Peer-Reviewed Original ResearchDisease-free intervalOncotype DXBreast cancer recurrenceClinical characteristicsBreast cancerC-indexHazard ratioCancer recurrenceStage I–III BC patientsEarly-stage breast cancerMultiple patient cohortsHarrell's C-indexDuctal histologyER/PR/HER2 statusHER2+BC subtypesBC patientsPatient cohortValidation cohortTNM stagePrediction of breast cancer recurrenceClinical variablesExternal cohortH&E slidesMultivariate analysis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply